Teleflex’s first quarter was marked by substantial year-on-year revenue growth, which outpaced Wall Street’s expectations and triggered a significant positive market reaction. Management credited the expansion to the inclusion of the recently acquired Vascular Intervention business and ongoing momentum across core product lines, particularly in vascular and surgical categories. Interim CEO Stuart Randle pointed to “strong execution” and noted that surgical instrument sales benefited from some favorable timing of orders, while integration activities in interventional products caused some temporary disruption. The quarter also included quality remediation costs related to supplier recalls, which contributed to the notable pressure on operating margins.
Is now the time to buy TFX? Find out in our full research report (it’s free for active Edge members).
Teleflex (TFX) Q1 CY2026 Highlights:
- Revenue: $548.3 million vs analyst estimates of $533.4 million (32.3% year-on-year growth, 2.8% beat)
- Adjusted EPS: $1.39 vs analyst estimates of $1.22 (13.9% beat)
- Adjusted EBITDA: $119.9 million vs analyst estimates of $107.4 million (21.9% margin, 11.7% beat)
- Management reiterated its full-year Adjusted EPS guidance of $6.40 at the midpoint
- Operating Margin: 3.7%, down from 18.3% in the same quarter last year
- Constant Currency Revenue rose 5.1% year on year (-3.8% in the same quarter last year)
- Market Capitalization: $5.76 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Teleflex’s Q1 Earnings Call
- Michael Matson (Needham & Company) asked about the potential for slower Q2 growth due to recalls and integration challenges. CFO John Deren acknowledged Q2 could be affected but expects acceleration in the second half as integration disruptions subside.
- Jayson Bedford (Raymond James) inquired about the balanced growth across segments and what will drive future outperformance. Deren highlighted strong performance in vascular and surgical, with interventional expected to become the main growth engine over time due to increased R&D focus.
- Matthew Taylor (Jefferies) questioned how input cost inflation, especially logistics, may affect margins. Deren noted logistics and distribution costs rose late in the quarter but believes ongoing efficiency programs will largely offset these headwinds.
- Ravi Misra (Truist Securities) sought details on the new board growth and operating committee, as well as regulatory timelines for the Freesolve trials. Interim CEO Randle said the committee will focus on execution of growth plans and confirmed European trial enrollment is ahead of schedule, with U.S. trials set for 2026.
- Shagun Singh Chadha (RBC Capital Markets) asked about the incoming CEO’s strategic vision and the timeline for an Investor Day. Randle said Weidman brings experience in complex global medtech portfolios and expects strategic updates once the new CEO is settled, with plans for an Investor Day in the future.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will closely monitor (1) the closure and integration of strategic divestitures, (2) the effectiveness of restructuring initiatives in reducing stranded costs and improving margins, and (3) the ramp-up of the Vascular Intervention business post-integration. We will also track progress in the Freesolve clinical trials and the timing and impact of planned share repurchases.
Teleflex currently trades at $130.16, up from $123.23 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
